The U.S. has added additional Chinese companies to its Entity List and Unverified List; China's State Council has taken steps to encourage foreign venture capital in the tech sector; and Chinese electrolyzer manufacturers are "Europeanizing" their products in anticipation of an EU crackdown.
Karen R King, partner at Morvillo Abramowitz Grand Iason & Anello P.C., and Jianwei (Jerry) Fang, partner at Zhong Lun Law Firm, describe how U.S. jurisdiction can reach Chinese nationals, and how to mitigate any personal risk
The U.S. publishes details on "Reverse CFIUS;" Shein's London listing might face obstacles; and two of the top 10 VC deals globally involve China, with much of the funding coming from Chinese state-backed investors.
Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
Philip Qu and Qiuchen Wang from TransAsia Lawyers analyze a pioneering approach to regulating cross-border data transfers recently adopted in one of Shanghai's free trade zones
International investors find Chinese secondary PE market an alternative amid U.S.-China tensions; QuantumPharm is the first IPO under Hong Kong's new measure for pre-revenue specialist technology firms; and China releases new carbon measuring standards foreseeing new EU carbon tariffs.
Apple wins antitrust case in China over app store fees; Temu is now subject to stricter EU online content rules; and Record Chinese investments flow into Mexico and Vietnam amid Western trade tensions.
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
